Elanco Launches New Canine Dermatology Drug Befrena
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Elanco Animal Health announced its latest entry into the canine dermatology space with the USDA approval of Befrena, a new anti-IL31 monoclonal antibody injection targeting canine allergic and atopic dermatitis. Befrena is recommended at a dosing interval of 6 to 8 weeks post-treatment, which stands in contrast to the 4 to 8 weeks of the current market competitor, lokivetmab. Elanco continues to expect to launch Befrena in the first half of 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELAN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELAN
Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is 25.50 USD with a low forecast of 22.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.120
Low
22.00
Averages
25.50
High
30.00
Current: 24.120
Low
22.00
Averages
25.50
High
30.00
About ELAN
Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gold and Silver Aren't the Sole Hot Commodities: Explore Agricultural Stocks.
Focus on Soft Commodities: The article emphasizes the importance of paying attention to soft commodities, which are often overshadowed by the rally in hard commodities like gold and silver.
Market Dynamics: It suggests that the current market dynamics warrant a closer look at soft commodities, as they may present significant investment opportunities.
Continue Reading
US Stocks Rise with Nasdaq Up 0.76% Amid Economic Optimism
- Positive Economic Data: Weekly initial jobless claims rose by 1,000 to 200,000, beating expectations of 209,000, indicating labor market resilience and boosting investor confidence in economic recovery.
- GDP Revision Upward: Q3 GDP growth was revised up by 0.1% to an annualized rate of 4.4%, surpassing the expected 4.3%, suggesting strong economic momentum that could further propel stock market gains.
- Surge in Natural Gas Prices: Natural gas prices rose over 3% to a three-year high due to an Arctic cold front increasing heating demand, which is expected to boost related stocks and invigorate the market.
- Strong Performance in Tech Stocks: The Magnificent Seven tech stocks saw significant gains, with Meta and Tesla rising over 5% and 4% respectively, reflecting strong market confidence in technology stocks that may lead the overall market higher.
Continue Reading